A phase 1 clinical trial just launched and will test the novel agent, CLN-978, for relapsed/refractory B-cell non-Hodgkin lymphoma. The first patient received treatment in a phase 1 clinical trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results